Phase I, Double-Blind, Randomized, Placebo-Controlled Trial in Healthy Volunteers to Examine Safety, Tolerability, Plasmapharmacokinetics of TMC589337andTMC589354 After Increasing Single Oral Doses and in an Open-Label Part After Different Repeated Doses in Combination With Single Oral Dose of TMC310911.

Trial Profile

Phase I, Double-Blind, Randomized, Placebo-Controlled Trial in Healthy Volunteers to Examine Safety, Tolerability, Plasmapharmacokinetics of TMC589337andTMC589354 After Increasing Single Oral Doses and in an Open-Label Part After Different Repeated Doses in Combination With Single Oral Dose of TMC310911.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2016

At a glance

  • Drugs TMC 310911 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Most Recent Events

    • 27 Oct 2016 Status changed from discontinued to withdrawn prior to enrolment.
    • 21 Jul 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 01 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top